ABSTRACT
(1) Introduction: The association between melanoma (MM) and the occurrence of second primary neoplasms (SPNs) has been extensively studied, with reported incidence rates ranging from 1.5% to 20%. This study aims to evaluate the occurrence of SPNs in patients with a history of primary MM and to describe the factors that make the risk higher in our population. (2) Material and Methods: We conducted a prospective cohort study and calculated the incidence rates and relative risks (RR) for the development of different SPNs in 529 MM survivors from 1 January 2005 to 1 August 2021. Survival and mortality rates were obtained, and the Cox proportional hazards model was used to determine the demographic and MM-related factors that influence the overall risk. (3) Results: Among the 529 patients included, 89 were diagnosed with SPNs (29 prior to MM diagnosis, 11 synchronous, and 49 after MM), resulting in 62 skin tumors and 37 solid organ tumors. The estimated probability of developing SPNs after MM diagnosis was 4.1% at 1 year, 11% at 5 years, and 19% at 10 years. Older age, primary MM location on the face or neck, and histologic subtype of lentigo maligna mm were significantly associated with a higher risk of SPNs. (4) Conclusions: In our population, the risk of developing SPNs was higher in patients with primary MM located on the face and neck and with the histological subtype of lentigo maligna-MM. Age also independently influences the risk. Understanding these hazard factors can aid in the development of MM guidelines with specific follow-up recommendations for individuals with the highest risk.
Subject(s)
Acitretin/administration & dosage , Keratoacanthoma/pathology , Lupus Erythematosus, Cutaneous/drug therapy , Lupus Erythematosus, Cutaneous/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Aged, 80 and over , Biopsy, Needle , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Keratoacanthoma/diagnosis , Keratoacanthoma/drug therapy , Leg Dermatoses/diagnosis , Lupus Erythematosus, Cutaneous/diagnosis , Prognosis , Risk Assessment , Skin Neoplasms/diagnosis , Treatment OutcomeABSTRACT
Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Sezary Syndrome/drug therapy , Skin Neoplasms/drug therapy , Aged , Alemtuzumab , Antigens, Differentiation, T-Lymphocyte/metabolism , Blood Cell Count , Humans , Male , Sezary Syndrome/blood , Skin Neoplasms/blood , Treatment OutcomeABSTRACT
Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Subject(s)
Humans , Male , Aged , Skin Neoplasms/drug therapy , Sezary Syndrome/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Skin Neoplasms/blood , Blood Cell Count , Antigens, Differentiation, T-Lymphocyte/metabolism , Sezary Syndrome/blood , Treatment Outcome , AlemtuzumabSubject(s)
Antineoplastic Agents/administration & dosage , Sarcoma, Kaposi/drug therapy , Skin Neoplasms/drug therapy , Timolol/administration & dosage , Administration, Cutaneous , Aged, 80 and over , Gels , Humans , Male , Remission Induction , Sarcoma, Kaposi/pathology , Skin Neoplasms/pathology , Treatment Outcome , Ultrasonography, Doppler, ColorABSTRACT
Eccrine hidrocystoma is a benign tumor derived from eccrine sudoriparous glands. Most eccrine hidrocystomas are solitary and asymptomatic lesions. Multiple hidrocystomas are unusual and have been associated with Graves' disease, Parkinson's disease, and idiopathic craniofacial hyperhidrosis. This report describes the successful treatment of multiple center facial eccrine hidrocystomas associated with craniofacial hyperhidrosis with 0.5% glycopyrrolate aqueous solution applied locally for 1 week. The present authors obtained a very significant improvement without leaving any trace of clinical examination. Multiple eccrine hidrocystomas are a rare condition and, to date, no effective treatment has been reported. Topical glycopyrrolate is a very good first-line treatment option.
